Bolt Biotherapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Bolt Biotherapeutics, Inc. (BOLT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $681.00K, a 9.13% increase year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $666.00K, a 8.29% increase year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $651.00K.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $636.00K, a 20.80% decline year-over-year.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.53M, a 9.97% increase from fiscal 2024.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.30M, a 22.19% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.95M, a 8.47% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $3.23M, a 30.09% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $681.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.35M 10-Q · filed 2026-08-11 | $2.00M derived: sum of 3 quarters · filed 2026-08-11 | $2.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $666.00K 10-Q · filed 2026-05-12 | $1.32M derived: sum of 2 quarters · filed 2026-05-12 | $1.95M derived: sum of 3 quarters · filed 2026-05-12 | $2.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.29M derived: sum of 2 quarters · filed 2026-03-12 | $1.91M derived: sum of 3 quarters · filed 2026-08-11 | $2.53M 10-K · filed 2026-03-12 |
| 2025-09-30 | $636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.26M derived: sum of 2 quarters · filed 2026-08-11 | $1.88M 10-Q · filed 2025-11-12 | $1.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.24M 10-Q · filed 2026-08-11 | $1.17M derived: sum of 3 quarters · filed 2026-08-11 | $1.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $615.00K 10-Q · filed 2026-05-12 | $548.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.35M derived: sum of 3 quarters · filed 2026-05-12 | $2.14M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $736.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.52M derived: sum of 3 quarters · filed 2026-03-12 | $2.30M 10-K · filed 2026-03-12 |
| 2024-09-30 | $803.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.59M derived: sum of 2 quarters · filed 2025-11-12 | $2.36M 10-Q · filed 2025-11-12 | $3.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $788.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.56M 10-Q · filed 2025-08-14 | $2.32M derived: sum of 3 quarters · filed 2025-08-14 | $3.06M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $773.00K 10-Q · filed 2025-05-12 | $1.53M derived: sum of 2 quarters · filed 2025-05-12 | $2.27M derived: sum of 3 quarters · filed 2025-05-12 | $3.01M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $758.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.50M derived: sum of 2 quarters · filed 2025-03-24 | $2.23M derived: sum of 3 quarters · filed 2025-03-24 | $2.95M 10-K · filed 2025-03-24 |
| 2023-09-30 | $744.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.48M derived: sum of 2 quarters · filed 2024-11-12 | $2.19M 10-Q · filed 2024-11-12 | $2.90M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $731.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.45M 10-Q · filed 2024-08-13 | $2.15M derived: sum of 3 quarters · filed 2024-08-13 | $2.84M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $719.00K 10-Q · filed 2024-05-14 | $1.42M derived: sum of 2 quarters · filed 2024-05-14 | $2.11M derived: sum of 3 quarters · filed 2024-05-14 | $2.77M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.39M derived: sum of 2 quarters · filed 2024-03-21 | $2.05M derived: sum of 3 quarters · filed 2024-03-21 | $3.23M 10-K · filed 2024-03-21 |
| 2022-09-30 | $682.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.35M derived: sum of 2 quarters · filed 2023-11-09 | $2.52M 10-Q · filed 2023-11-09 | $3.06M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.84M 10-Q · filed 2023-08-07 | $2.38M derived: sum of 3 quarters · filed 2023-08-07 | $3.14M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $1.17M 10-Q · filed 2023-05-11 | $1.72M derived: sum of 2 quarters · filed 2023-05-11 | $2.48M derived: sum of 3 quarters · filed 2023-05-11 | $3.12M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.30M derived: sum of 2 quarters · filed 2023-03-29 | $1.95M derived: sum of 3 quarters · filed 2023-03-29 | $2.48M 10-K · filed 2023-03-29 |
| 2021-09-30 | $761.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.41M derived: sum of 2 quarters · filed 2022-11-10 | $1.94M 10-Q · filed 2022-11-10 | $2.48M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $644.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.17M 10-Q · filed 2022-08-10 | $1.72M derived: sum of 3 quarters · filed 2022-08-10 | $2.18M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $530.00K 10-Q · filed 2022-05-12 | $1.07M derived: sum of 2 quarters · filed 2022-05-12 | $1.54M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $541.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.01M derived: sum of 2 quarters · filed 2022-03-30 | $1.89M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $467.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.35M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $885.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |